|

GTB-360 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: anti-CD16/IL-15/anti-CD33

Pipeline

Phase 1: 1

Top Sponsors

  • Masonic Cancer Center, University of Minnesota1

Indications

  • Acute Myeloid Leukemia1
  • Myelodysplastic Syndromes1
  • Myeloid Malignancy1
  • Cancer1

Minneapolis, Minnesota1 trial

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Masonic Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.